



3biotix Pharma is dedicated to the development of cutting-edge anti-inflammatory, antimicrobial and antibiofilm agents that can prevent and treat infections, while overcoming drug resistance.



THE NEXT GLOBAL PANDEMIC CAN BE CAUSED BY RESISTANT BACTERIA OR FUNGI. WE HOLD THE INNOVATION TO FIGHT IT.

"Never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent" | WHO

If the rise in resistance continues, the world would be facing 10M deaths per year | \$100 Trillion global economic burden.

The role of biofilm | Microorganisms grow as a community

Biofilm is an extracellular matrix that is self-produced by a spectrum of microorganisms and can form on a variety of surfaces (including skin and mucosal tissues). Biofilm allows both bacteria and fungi to communicate through a process called Quorum Sensing (QS) and protect themselves against many therapeutic agents.

Shifting paradigms in prevention and treatment of infectious diseases

Our patent-pending platform of anti-inflammatory antimicrobial and antibiofilm agents is based on a unique formulation of cannabinoids that have shown the ability to disrupt quorum sensing and damage biofilm structure, motility, metabolic activity and gene expression.

Investment highlights:

- Answering serious unmet needs** in infectious diseases and women health markets
- First product a non-toxic "double threat" solution:** antibiofilm, & anti-inflammatory
- From the labs of the Hebrew University**
- Rich future pipeline** of innovative OTC products and Rx.
- Seeking a \$1.2M investment** as seed funding for completion of formulation design, in vitro and clinical testing within 18 months.

Strong team

- Alon Barzilay** | Founder & CEO; An experienced entrepreneur.
- Prof. Doron Steinberg** | Founder & CTO; Head of Biofilm Research Lab, HU
- Amir Bassan, Moshe Blumenkrantz** Founders CFO & BD

Renowned medical advisors

- Prof. Daniel Seidman** | OBGYN Unit director, Sheba; Associate Professor, TAU
- Ifat Hammer** | Ifat has Over 20 years of experience in formulation design and holds several patents.

Disrupts, instead of killing

Unlike most antimicrobials, it reduces microbes' ability to develop resistance.

Non toxic

None of the serious side effects (and hence, costs) typically associated with antibiotics.

Broad spectrum

Fight a variety of different infections caused by both bacteria and fungi.




Backed by science | groundbreaking research by the Biofilm Research Lab, Hebrew University


In fungi, it has shown to Inhibit Yeast-To-Hyphal Transition, preventing fungi to develop Into pathogens.

in vitro results show Effect on Candida albicans visibility in biofilm:


Untreated control



100 CBG ML



200 CBG ML



Solid strategy

We've identified indications in which:

- Biofilm is a key player
- High prevalence of the problem and a huge market
- OTC products with major impact and minimum regulation
- Ability to expand offering with Rx products

Yeast Vaginitis - Our first indication:

75% of women worldwide will suffer at least once from yeast vaginitis - **VVC** and recurrent **VVC** (called **RVVC**).

Candida albicans is responsible for the majority of infections in women with **VVC** or **RVVC**.

Dozen of millions of women suffer annually from **VVC** or **RVVC**.

Antifungals products are toxic, limited in efficacy and prevention.

\$1.5B yeast vaginitis market In developed countries. Revenues to expand at CAGR of **5.1%**.

Our solutions

Treatment: 1) Medical device combined with a gel for intra-vaginal treatment for **VVC**.

2) Medical device combined with a gel for intra-vaginal treatment for **RVVC**.

Both regulates under class II medical device, 510K pathway.

In the Pipeline:

1) Medical device combined with a "Double Threat Gel" "Double Threat" for bacterial and yeast vaginitis (Two solutions in one product).

2) Prevention OTC Skin protectant drug product (existing monograph) for RVVC.

3) Rx drug for RVVC patients.

\$2.7B vaginitis market today. Market revenues will expand at CAGR of 5.1% **to \$4.5B IN 2030**.

We have a strong vision to become leaders in antimicrobial innovation, leveraging our access to cutting edge science to keep identifying new technologies and bring them to market.

We invite you to join us.

info@lvs-partners.com